French biopharmaceutical company Pharnext has announced a research and development (R&D) agreement with Galapagos to generate a new pipeline of synergistic drug combinations.
Galapagos NV (Euronext & NASDAQ: GLPG) announced that its Board of Directors created 150,000 warrants under a new warrant plan for the benefit of an employee of a subsidiary of the Company.